Lead drug candidate receives positive opinion from EMA
Filed with ASX · · 2 pages · English
Alterity Therapeutics Ltd. on 6ix
Earlier from Alterity Therapeutics
- Appendix 4E & Annual Report 2019
- Successful Completion of Phase 1 Clinical Trial
- Alterity presents initial Phase 1 clinical trial data at AAN
- Prana receives A$3.3 million R&D Tax Incentive Refund
- Orphan Designation for PBT434 for treatment of MSA
Later from Alterity Therapeutics
- Chairmans Address to Shareholders
- AGM Presentation 2019
- European Orphan Designation granted for PBT434 for MSA
- Alterity receives a $4.8 million R&D Tax Incentive Refund
- Appendix 4C - quarterly
Follow Alterity Therapeutics into a list and get an email when it puts out news.
Follow Alterity Therapeutics